CClinicalTrials.gg
WithdrawnNCT01661348Updated Oct 16, 2013

The Use of the Prevena Incision Management System to Reduce Post-operative Cesarean Delivery Wound Complications

An observational study in Pregnancy, sponsored by University of Oklahoma. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-10-16.

Sponsored by University of Oklahoma · Observational

Why this study was withdrawn
Did not receive funding.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Aim 1: Assess the effectiveness of the Prevena Incision Management System in decreasing postoperative surgical site infections in the obese parturient undergoing non-emergent cesarean delivery.

Aim 2: Assess patient satisfaction after using the Prevena Incision Management System following a non-emergent cesarean delivery.

Our overall long term goal is to reduce morbidity and incidence of surgical site infection (SSI) in obese parturient who undergo non-emergent cesarean delivery.

Read the detailed description

In the United States, the cesarean delivery rate continues to rise. In 2007, approximately 32% of all births occurred by Cesarean delivery, translating to 1.4 million women who underwent this operative procedure. Oklahoma is on par with the national average, with 33.6 % of births occuring by Cesarean delivery (1). Although in 2006 Cesarean delivery was the most commonly performed surgical procedure in the United States, it remains vulnerable to common, as well as rare, complications. Despite continued advances in surgical and aseptic technique, surgical site infections (SSI) continue to be an area of concern for patients, physicians, hospitals, and insurers.

In addition to their negative impact on patient quality of life, surgical site infections (SSI) have been estimated to require an additional three thousand dollars per infection in healthcare expenditure (2). In the surgical patient, it has been estimated that SSI account for 25 to 38% of hospital acquired infections (3-4) and 2-5% of patients undergoing surgery of any type will develop a SSI (5). In cesarean delivery in particular, rates of SSI are between 3 to 15%, depending on the population, definition of SSI, and modifiable risk factors (6). In particular, one factor shown to increase risk of SSI in multiple studies is obesity with odds ratios 1.1-4.79 depending on degree of BMI stratification (6-8). Given its prevalence and cost, SSI represents a postoperative complication with far reaching consequences and making it an area of increasing focus for research.

Recently, negative pressure wound therapy has come to the forefront in demonstrating improved healing and reduced complications in open and closed surgical wounds of various types. A review of the literature illustrates that prophylactic negative pressure wound therapy device effectiveness in reducing SSI has not been widely evaluated in cesarean deliveries. The goal of this study is to evaluate wound infection rates with the use of the Prevena Incision Management System in obese patients undergoing non-emergent cesarean delivery at a tertiary care center. We propose to initiate a randomized clinical trial of the Prevena Incision Management System in a novel population of patients at high risk of surgical site infection. Given the possibility of unexpected challenges, we propose to begin this project with a pilot study in order to help elucidate factors that may need to be including in a larger study in the future. Also, we anticipate that the pilot study will give us a better insight into the rates of wound complications and potential difference between groups in order to better power a larger study.

Rationale for study: Obese patients undergoing Cesarean deliveries have frequent SSIs secondary to modifiable and non-modifiable risk factors. A randomized controlled trial of Prevena Incision Management System, a single use negative pressure therapy unit designed for placement over clean closed surgical incisions, will help reduce rates of surgical site infections and increase the overall quality of life of our patients.

02

Conditions studied

  • Pregnancy

Browse trials for

Keywords

  • Cesarian section
  • Pregnancy
  • Incision management
03

In context

Surgical Wound

519 studies on the registry are indexed under Surgical Wound; 71 are open to participants now.

Browse Surgical Wound studies →

Lead sponsor

University of Oklahoma is the lead sponsor of 424 studies on the registry; 99 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All eligible patients will be approached for consent to participate in the study prior to surgical procedure.

Inclusion criteria

  • Women greater than or equal to 18-years-of-age having a non-emergent Cesarean delivery, primary or repeat procedure, without evidence of active infection at the time of the procedure

    • Patient with BMI ≥ 30 kg/m2 at the time of hospital admission
    • Patient able to provide informed consent for study
    • Patient able to complete follow-up

Exclusion criteria

Exclusion Criteria:

  • Males

    • Females under the age of 18
    • Known sensitivity to silver due to the presence of silver in the skin interface layer of the Prevena
    • Patients unable to consent
    • Patients in active labor
    • Patients with a diagnosis of preterm premature rupture of membranes
    • Patients with known or suspected infection at the time of Cesarean delivery
    • Patients with a contraindication to use of the Prevena Incision Management System
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
0 participants (actual)

Groups and cohorts

  • Prevena System placement

    Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group).

  • Standard of care postoperative care

    Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group).

06

What researchers measure

Primary outcomes

  1. Rate of Wound Infections

    Time frame: The percent of patients with wound infections will be summarized at the 5-7 day post-operative assessment, the 14-21 day post-operative assessment, and the 6-week follow-up visit. The rate of wound infections will be evaluated at each time point.

07

Study locations

1 site
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01661348
Lead sponsor
University of Oklahoma
Responsible party
Sponsor
First posted
Aug 9, 2012
Start date
Jul 2012
Primary completion
Jul 2014 (estimated)
Completion
Jul 2014 (estimated)
Last update
Oct 16, 2013

Study contacts

Katherine M Smith, MD
principal investigator · University of Oklahoma
Elise Eckhardt, MD
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion